Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis

Table 1 Risk of bias domains to be evaluated on equivalence or non-inferiority trials

Type of bias	Domain	Source
Selection bias	Random sequence generation	Cochrane RoB tool 1.0
	Allocation concealment	Cochrane RoB tool 1.0
	Inconsistent application of inclusion/exclusion criteria	US Agency for Healthcare Research and Quality
Performance bias	Blinding of participants and investigators	Cochrane RoB tool 1.0
Performance bias	Participants behavior changes	US Agency for Healthcare Research and Quality
Detection bias	Blinding of outcome assessment	Cochrane RoB tool 1.0
Detection bias	Outcome measurement techniques	US Agency for Healthcare Research and Quality
Attrition bias	Incomplete outcome data	Cochrane RoB tool 1.0 and US Agency for Healthcare Research and Quality

Sources: Cochrane Risk of Bias in randomized trials (RoB 1.0.) described in the Cochrane Handbook for Systematic Reviews of Interventions [36] and the US Agency for Healthcare Research and Quality recommendations [24]

ISSN: 2046-4053